PRIMA-1MET induces death in soft-tissue sarcomas cell independent of p53
- 1.3k Downloads
The aim of this study was to explore the efficacy and define mechanisms of action of PRIMA-1MET as a TP53 targeted therapy in soft-tissue sarcoma (STS) cells.
We investigated effects of PRIMA-1MET on apoptosis, cell cycle, and induction of oxidative stress and autophagy in a panel of 6 STS cell lines with different TP53 status.
Cell viability reduction by PRIMA-1MET was significantly observed in 5 out of 6 STS cell lines. We found that PRIMA-1MET was capable to induce cell death not only in STS cells harboring mutated TP53 but also in TP53-null STS cells demonstrating that PRIMA-1MET can induce cell death independently of TP53 in STS cells. We identified an important role of reactive oxygen species (ROS), involved in PRIMA-1MET toxicity in STS cells leading to a caspase-independent cell death. ROS toxicity was associated with autophagy induction or JNK pathway activation which represented potential mechanisms of cell death induced by PRIMA-1MET in STS.
PRIMA-1MET anti-tumor activity in STS partly results from off-target effects involving ROS toxicity and do not deserve further development as a TP53-targeted therapy in this setting.
KeywordsSoft tissue sarcoma Apoptosis Oxidative stress PRIMA-1MET p53
Fluorescent Activating Cell Sorting
Mouse double minute 2
Mitogen-activated protein kinase
Mitochondrial membrane potential
Methyl Thiazolyl Tétrazolium
National Cancer Institute
Phosphate buffered saline
Reactive oxygen species
Standard error of the mean
Stress-activated protein kinase
Tetramethylrhodamine Methyl Ester
Well-planned wide surgical excision complemented by adjuvant radiotherapy in cases of large (>5 cm) and/or deep tumors is the standard loco-regional treatment for soft-tissue sarcoma (STS) patients [1, 2]. However, despite optimal local treatment, 30 to 40 % of patients will develop metastatic disease . Doxorubicin is considered as the standard first-line therapy for patients with advanced STS and median overall survival is only 12–18 months . New therapies are therefore needed in this setting.
TP53 is a transcription factor also called “guardian of genome”, activated under stress conditions, leading to apoptosis induction and cell cycle arrest . Our research group has previously shown that the p53 pathway is commonly dysregulated in STS  with mutations found in more than 50 % of STS with complex genomics profiles. Mutations affecting TP53 cause misfolded protein and/or lack of DNA interaction capacity , (http://p53.iarc.fr/) with the result of lack of tumor suppressor function and more recently discovered an oncogenic gain function . More than 80 % of the mutation occurs in the DNA-binding domain of the gene preventing correct transcription activity . Based on its crucial role in carcinogenesis and the frequent dysregulation of the p53 pathway in cancer, TP53 represent an appealing target for mechanism-driven anticancer drug discovery.
Nutlins, which prevent p53 proteasomal degradation via MDM2 interaction  has proven some preclinical efficacy and is now under early clinical phase development. In 2002, Bykov et al.  isolated from the low molecular weight compound library of the National Cancer Institute, a compound that can restore wild-type function to mutant p53, called PRIMA-1 for P53 Reactivation and Induction of Massive Apoptosis. The described molecular mechanism of action is based on the conversion of PRIMA-1 into compounds that form adducts with thiols in mutant TP53 allowing transcription activation . Demonstration of the in vitro and in vivo activity of PRIMA-1 or its methylated form, PRIMA-1MET, in terms of apoptosis induction [11, 12, 13] and cell cycle arrest [12, 13] has been reported in different tumor models. There is no data regarding the activity of PRIMA-1MET in STS.
The aim of our study was to obtain preliminary proof of efficacy of PRIMA-1MET in STS cell lines and to assess its specific mechanism of action regarding TP53.
The STS cell lines, IB130 (pleiomorphic liposarcoma/ mutant TP53 exon 8, P278L), IB134 (uterine leiomyosarcoma/mutant TP53 exon 6, S215R), IB136 (soft-tissue leiomyosarcoma, null TP53), IB117 (myxofibrosarcoma, null TP53), IB138 (soft-tissue leiomyosarcoma/mutant TP53 exon 5, V143M), and IB139 (soft tissue leiomyosarcoma, wild-type TP53) used in this study have been derived from human surgical specimen of STS in the laboratory of Pr. Jean-Michel Coindre and Dr Frédéric Chibon (Institut Berognié, Bordeaux, France) and after having obtained patient consent. For all the cell lines, TP53 status was assessed by Sanger sequencing, array-comparative genomic hybridization and western blotting (protocols are available on request). Colon carcinoma cell lines used were HCT-116 (wild type TP53) and HT-29 (mutant TP53 exon 8, R273H) purchase from the NCI (http://discover.nci.nih.gov/cellminer/). All cell lines were cultured in complete RPMI 1640 (Sigma Life Technologies, Saint Louis, MO) with 10 % Fetal calf serum, Penicillin/Streptomycin 1 %, and Normocin 0.2 %.
PRIMA-1MET and Staurosporin were purchased from Santa Cruz Biotechnology INC (Heidelberg, Germany). PRIMA-1MET was stored at −20 °C and diluted in water. Chloroquine Diphosphate salt and N-acetyl-L-cysteine were purchased from Sigma Life Science (Saint Louis, MO).
Three thousand cells were seeded in 96-well plates for 24 hr and treated with a range of increasing concentrations of PRIMA-1MET for 24 hr to 96 hr. Methyl Thiazolyl Tétrazolium (MTT, Sigma Aldrich, St Quentin Fallavier, France) was applied for 3 hours before being dissolved in dimethylsufoxyde (final concentration: 0.5 mg/mL). Quantity of produced formazan was measured by spectrophotometry. Absorbance was measured at 570 nm with a reference at 630 nm. Analysis was done by using the KC4 software (Kinetical for Windows V.3.4) and IC50 was calculated with GraphPad Prism version 5.00 for Windows (GraphPad Software, La Jolla California USA, www.graphpad.com).
Fluorescent cell sorting analysis (FACS)
Apoptosis and cell cycle were evaluated using Fluorescent Activating Cell Sorting (FACS) analysis. For mitochondrial membrane depolarization studies, 3000 cells were seeded in 96-well plates for 24 hours and treated with a range of increasing concentrations of PRIMA-1MET for 72 hours, then incubated for 30 min with Tetramethylrhodamine Methyl Ester (TMRM). P-glycoprotein drug efflux pump was blocked using Verapamil (Sigma-Aldrich, St Quentin Fallavier, France). For activated caspases 3 and 7 detection, 5.105 cells were seeded in 6-wells plates for 24 hours, treated with increasing doses of PRIMA-1MET for 72 hours and 96 hours, respectively. Cells were harvested and exposed to FLICA 1X as described by the supplier (FAM-FLICA™ Kit, ImmunoChemistry Technologies, Bloomington, USA) for 1 hour. For apopotosis/necrosis assay, 1.106 cells were seeded in 6-wells plates for 72 hours, then treated and exposed to FITC-Annexin and propidium iodide (PI) according the manufacturer’s protocol (BD Biosciences, Erembodegem, Belgium). This allowed distinguishing annexin V positive cells in early apoptosis, versus annexin V and PI positives cells in late apoptosis or necrosis. For cell cycle analysis, 1.105 cells were seeded in 6-wells plates and after 24 hours cells were treated with PRIMA-1MET for 48 hours to 96 hours. Cells were then fixed and permeabilized in absolute ethanol with PBS over-night at −20 °C, then rinsed and incubated with RNase and Propidium Iodide (50 μg/mL) (Sigma Aldrich, St Quentin Fallavier, France). For ROS production assay, 6000 cells were seeded in 96-well plates for 24 hours and treated with PRIMA-1MET for 96 hours, then incubated for 30 min with 2',7'-Dichlorofluorescin diacetate (DCFDA) 20 μM (Abcam, Cambridge, MA, USA). We performed flow cytometry analysis using FL1 for TMRM, FAM-FLICA, Annexin-V and DCFDA, whereas FL2 was used for Propidium iodide. Flow cytometry (FACSCalibur; BD Biosciences, San Jose, USA) data were analyzed with FlowJo v.7.6.3. software.
The physical lysis « Ultimate freeze-thaw lysis for mammalian cells » protocol was used for non-phosphorylated protein extraction . For autophagy and phosphorylated protein, Radio-ImmunoPrecipitation Assay (RIPA) lysis buffer protocol  was used. Total proteins (30-60 μg) were separated by 10 or 12 % SDS-PAGE and transferred on Polyvinyl Difluoride (PVDF) membrane. The following antibodies were purchased from Cell Signaling Technology (Danvers, USA): anti-BAX (1:500), anti-PUMA (1:1000), anti-JNK (1:1000) and anti-phospho JNK monoclonal antibodies (1:1000). Anti-GAPDH (1:200) and anti-p53 (1:1000) monoclonal antibodies were purchased from Santa Cruz Biotechnology (Heidelberg, Germany). The anti-p21 monoclonal antibody (1:33) was purchased from Calbiochem (San Diego, USA). The anti-LC3IIB monoclonal antibody (1:1000) was purchased from Sigma Aldrich (Saint Louis, USA) and the anti-PARP monoclonal antibody (1:1000) was purchased from EnzoLifeSciences (Farmingdale, USA). Secondary antibodies anti-Mouse IgG and anti-Rabbit IgG (1:5000) were purchased from Ge Healthcare (Buckinghamshire, United Kingdom). Proteins were detected (Fusion Fx7, Fisher Bioblock Scientific, Waltham, MA, USA) by using enhanced chemiluminescent substrate for horseradish peroxidase (HRP) (Immobilon™ Western, Millipore Corporation). Each membrane was reused 3 times after desaturation in glycin (6.6 mol/L) buffer pH = 2 at 56 °C for 30 min. Semi-quantitative analysis was realized with ImageJ 1.45 s software (Rasband, W.S., ImageJ, U. S. National Institutes of Health, Bethesda, Maryland, USA, http://imagej.nih.gov/ij/, 1997–2014).
Cells were seeded on coverslips and treated with PRIMA-1MET for 72 hours. Slides were then washed twice with PBS, fixed in formaldehyde 4 % and incubated with anti-LC3IIB monoclonal antibody (Sigma Aldrich, Saint Louis, USA) overnight, and then with a goat anti-rabbit Alexa fluor 488 antibody (Invitrogen, Paisley, United Kingdom). Slides were then counterstained by 4,6-diamidino-2-phenylindole (DAPI).
Prima-1MET reduces STS cells viability independently of p53 status
PRIMA-1MET does not induce apoptosis in STS cell lines
PRIMA-1MET does not induce p53-dependent cell cycle arrest in STS cell lines
One of the putative mechanisms of action of PRIMA-1MET is restoring p53 functions as a sequence-specific transcription factor that drives the transactivation of target genes mediating cell-cycle arrest [10, 12, 13]. Treatment of STS cells for 24, 48 or 72 hours with PRIMA-1MET did not result in dose dependent cell cycle arrest and induction of P21. PRIMA-1MET induced cell cycle arrest in HCT-116 cells in a dose dependent manner (data not shown). Those results combined with the lack of apoptosis suggest that PRIMA-1MET effect is largely p53 independent in STS cells.
PRIMA-1MET-induced STS cells death is associated with a loss of mitochondrial membrane potential (MMP) and reactive oxygen species (ROS) toxicity independently of the p53 status
PRIMA-1MET induces autophagy and activates JNK pathway in STS cell lines independently of TP53 status
ROS-dependent activation of JNK has been identified as a crucial mechanism of cell death . We found that PRIMA-1MET induced JNK phosphorylation (p-JNK) in IB130 and IB139 cell lines but not in IB134, IB136 and IB138 (Fig. 4c). p-JNK was also induced in HT-29 cells (data not shown).
We report here the first study investigating PRIMA-1MET activity in STS by using 6 cell lines with different TP53 status. First, we found that PRIMA-1MET altered significantly cell viability in 5 out the 6 cell lines, two of them harboring a homozygous deletion of TP53. This result suggested a mechanism of action of PRIMA-1MET at least in part independent of TP53. PRIMA-1MET was first isolated based on its specific action on TP53 mutated cell lines and its ability to re-induce P53 dependent pathway . However, several studies have shown that PRIMA-1MET can induce cell death even in tumor models with no mutation or deletion of TP53 [11, 19, 20] suggesting TP53-independent mechanisms of action. Recently, Sobhani et al. show that siRNA knockdown of P53 did not influence the PRIMA-1MET-induced cell death in Waldenström macroglobulinemia cells . Our results are in perfect agreement with those of Sobhani et al.  and confirm that PRIMA-1MET might involve more complex mechanisms than those originally described  not restricted to a P53 transcriptional related activity .
The second striking result was that PRIMA-1MET did not induce significant caspase-dependent-apoptosis in STS. Indeed, contrary to that observed in other tumor models [13, 22, 23], we did not found any caspase-3 activation when STS cells were treated with PRIMA-1MET. It was therefore apparent that the PRIMA-1MET-induced cell death in STS was following a caspase-independent pathway.
Oxidative stress is a common form of cellular stress and refers to an imbalance of the production and clearance of cellular oxidants resulting in high concentration of ROS and oxidative damage. Due to their high reactive potential in reducing-oxidizing reactions, ROS can oxidize lipids, proteins, and nucleic acids, which in turn compromise the normal cellular functions of these macromolecules leading to growth arrest, cell senescence, and even cell death . Because PRIMA-1MET was reported to induce ROS [10, 16, 17], we assessed endogenous ROS production, in our panel of STS cell lines. Indeed, we found an increase of ROS production in STS cells treated with PRIMA-1MET, irrespective of the presence of TP53 and this increase was inhibited by NAC. The addition of NAC counteracted cell growth inhibition induced by PRIMA-1MET in our STS cell lines. Altogether, these results indicate that ROS induction play a crucial role in PRIMA-1MET-induced cell death in STS as reported in other tumor models [16, 17].
Mechanisms involved in cell death resulting from ROS induction are not fully elucidated yet. However, in vitro studies from mammalian cells suggested that ROS regulate autophagy in various cell lines as exogenous oxidative stressors induce autophagy . By assessing LC3-II levels, we showed here that treatment with PRIMA-1MET induced autophagy in STS cells. We observed this effect in two STS cell lines with mutated TP53 and in the wild-type and the mutated colon carcinoma cell lines. This suggests that induction of autophagy by PRIMA-1MET is at least in part independent of the mutational status of TP53. Our results are in agreement with those reported by Russo et al.  indicating that PRIMA-1MET can trigger autophagy in cancer cells regardless of the presence of TP53 and identified autophagy as a potential crucial pathway leading to STS cell death induced by PRIMA-1MET. Since relation between autophagy and cell death is still controversial , this will require further investigation.
The JNK pathway is a well-conserved mitogen-activated protein kinase (MAPK). JNK was first identified as a stress-activated protein kinase (SAPK) that responds to various stresses in mammalian cells . It has been known for a long time that JNK can be activated by exogenous ROS. Moreover, data from cell culture substantiates the notion that JNK activated by oxidative stress jeopardizes cell survival as a pro-death signal . Li et al. reported that PRIMA-1MET induced cell death through the JNK pathway in a p53-dependent manner in colorectal cell lines . Interestingly, we found here that PRIMA-1MET induced JNK activation in IB130 (mutated TP53) and IB139 (wild-type TP53) indicating that this process was at least in part independent of TP53. Moreover, JNK activation was not present in STS cell lines for which PRIMA-1MET induced autophagy. This may suggest that autophagy induction and JNK activation may represent alternative mechanism of STS cell death resulting from oxidative stress induced by PRIMA-1MET. Our experimental conditions applied on colon carcinoma cell lines equally shown that cell death was not caspase dependent and that PRIMA-1MET toxicity is not dependent of TP53 status but largely involve oxidative stress.
In conclusion, our results confirm that the mechanisms of action of PRIMA-1MET are more complex than firstly described. We demonstrate here that PRIMA-1MET anti-tumor activity in STS is P53-independent and results mainly from off-target effects involving ROS-associated toxicity without significant induction of caspase-dependent-apoptosis. For this reason, PRIMA-1MET does not deserve further development as a TP53-targeted therapy in STS. However, further studies may be warranted to assess potential synergy of PRIMA-1MET with recognized active drugs in STS that interfere also with the ROS pathway such as doxorubicin .
The authors thank Pippa McKelvie-Sebileau of Institut Bergonié for medical editorial services. This study was supported by the French National Institute of Health and Medical Research (INSERM grant “Soutien pour la formation à la recherche translationnelle en cancérologie”).
- 14.Tansey WP. Freeze-thaw lysis for extraction of proteins from Mammalian cells. CSH Protoc. 2006;2006(7).Google Scholar
- 15.Harlow E, Lane D. Lysing tissue-culture cells for immunoprecipitation. CSH Protoc. 2006;2006(4).Google Scholar
- 17.Tessoulin B, Descamps G, Moreau P, Maïga S, Lodé L, Godon C, et al. PRIMA-1Met induces myeloma cell death independently of p53 by impairing the GSH/ROS balance. Blood. 2014;124:1626-36.Google Scholar
- 24.Miwa S, Muller FL, Beckman KB. The Basics of Oxidative Biochemistry. In Oxidative Stress in Aging; 2008. p. 11–35.Google Scholar
- 26.Russo D, Ottaggio L, Foggetti G, Masini M, Masiello P, Fronza G, et al. PRIMA-1 induces autophagy in cancer cells carrying mutant or wild type p53. Biochim Biophys Acta. 1833;2013:1904–13.Google Scholar